Natco Pharma Limited today said its consolidated Profit After Tax (PAT) for the quarter ending March 31, 2018 was up by nearly 70 per cent to Rs 300 crore as against Rs 176.4 crore during the same quarter in FY'17. A press release from the city-based drug-maker said the company recorded a net revenue of Rs 788 crore, on a consolidated basis during the quarter as against Rs 577.2 crore in Q4, 2017, an increase of 36.50 per cent. For the full FY '18,total revenuewas Rs 2,242.2 crore against Rs2,079 crorein FY '17 while net profit was Rs 695.2 crore as againstRs485crore, a growth of 43.37per cent.
For suggestions and feedback click here.
Disclaimer: IMC is not responsible for any kind of loss arising due to the information. You are receiving this newsletter because you have subscribed to this service. To unsubscribe click here. Head Office : IMC Bldg., IMC Marg, Churchgate, Mumbai - 400 020 India | Tel : 91-22-71226633 | Fax : 91-22-22048508 / 22838281 E-Mail : imc@imcnet.org | Website : www.imcnet.org